Form D · Pharmaceuticals
Pharmaceutics International, Inc.
Hunt Valley, MD · CIK 0001684470
Offering snapshot reported Oct 23, 2024 · SEC filing
- Reported sold
- $11.2M Offering amount: $11.2M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 3, 2024 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$4,249,990 → $11,249,998
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 23, 2024 | Amendment | $11,249,998 | $7,000,008vs Jun 11, 2024 | 3 | SEC filing |
| Jun 11, 2024 | Initial | $4,249,990 | No comparison | 3 | SEC filing |
| Mar 13, 2024 | Initial | $4,249,989 | No comparison | 6 | SEC filing |
| Jun 27, 2023 | Initial | $6,000,000 | No comparison | 2 | SEC filing |
| Dec 12, 2022 | Initial | $3,000,159 | No comparison | 5 | SEC filing |
| Oct 7, 2022 | Initial | $9,007,812 | No comparison | 5 | SEC filing |
| Aug 22, 2022 | Initial | $5,000,319 | No comparison | 5 | SEC filing |
| Jul 12, 2022 | Initial | $5,000,319 | No comparison | 5 | SEC filing |
| May 5, 2022 | Initial | $5,000,000 | No comparison | 4 | SEC filing |
| Mar 17, 2022 | Initial | $5,000,319 | No comparison | 4 | SEC filing |
| Jan 11, 2022 | Initial | $5,000,159 | No comparison | 2 | SEC filing |
| Oct 29, 2021 | Initial | $5,000,159 | No comparison | 2 | SEC filing |
| Aug 6, 2021 | Initial | $6,000,000 | No comparison | Not reported | SEC filing |
| Jun 4, 2021 | Initial | $10,000,000 | No comparison | Not reported | SEC filing |
| Jun 4, 2021 | Initial | $3,000,159 | No comparison | Not reported | SEC filing |
| Oct 29, 2018 | Initial | $5,971,142 | No comparison | 5 | SEC filing |
| Aug 15, 2017 | Initial | $9,999,522 | No comparison | 6 | SEC filing |
| Sep 14, 2016 | Initial | $107,999,363 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-515696
Source: Form D, filed Oct 23, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sana I. Abidi | Director |
| Shahab N. Abidi | Director |
| Syed E. Abidi | Director |
| Syed E Abidi, Ph.D. | Director |
| Michael Bogda | Director |
| Jillian Dettinger | Executive |
| Gerard Fleury | Executive |
| John Fowler | Director, Executive |
| James Gale | Director |
| John Guthrie | Executive |
| Julien Hecht | Executive |
| Mark Kavulich | Director |
| Joseph Kiely | Executive |
| Kurt Nielsen, Ph.D. | Director, Executive |
| Shahid Raza | Director |
| David Solomon | Director |
| George Svokos | Director |
| Kevin Walsh | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
10819 Gilroy Road
Hunt Valley, MD, 21030
Hunt Valley, MD, 21030